Exchange: NASDAQ·Updated 07:30 PM EDT

UTHR News

News
all
press releases
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
Zacks
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso to Treat Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso (treprostinil) Inhalation Solution to treat IPF. United Therapeutics anticipates the agency's review to be...
Business Wire
Top Research Reports for Toyota Motor, CrowdStrike & Welltower
Toyota Motor's hybrid growth and expanded value-chain businesses support demand, but higher costs, China weakness and leverage temper prospects.
Zacks
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fireside chat sessions at four upcoming investor conferences. Martine Rothblatt, Chairperson and Chief Executive Officer, will present at the Wells Fargo 21st Annual...
Business Wire
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Zacks
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
Zacks
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in...
Business Wire
Will LQDA's Differentiated PAH Approach Drive Growth?
LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
Zacks
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved...
Business Wire

Advertisement|Remove ads.